Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston, MA (M.R.M.).St. Vincent Heart Center, Indianapolis, IN (C.S.).University of Colorado School of Medicine, Aurora (J.C.C.).Icahn School of Medicine at Mount Sinai, New York, NY (S.P.).Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, NY (M.Y.).Duke Heart Center, Duke University, Durham, NC (C.A.M.).Washington University School of Medicine, St. Louis, MO (A.I.).Montefiore Einstein Center for Heart and Vascular Care, New York, NY (D.J.G.).University of Chicago School of Medicine and Medical Center, IL (N.U.).Carolinas Medical Center, Charlotte, NC (S.G.).University of Michigan Health System, Ann Arbor (F.D.P.).University of Minnesota Medical Center, Minneapolis (R.J.).Sharp Memorial Hospital, San Diego, CA (R.A.).Bon Secours St. Mary’s Hospital, Richmond, VA (R.B.).Aurora St. Luke’s Medical Center, Milwaukee, WI (V.T.).Abbott, Abbott Park, IL (J.C., P.S., S.G.).Florida Hospital, Orlando (S.C.S.).
Checking for direct PDF access through Ovid
Background:The MOMENTUM 3 trial compares the centrifugal HeartMate 3 (HM3) with the axial HeartMate II (HMII) continuous-flow left ventricular assist system in patients with advanced heart failure, irrespective of the intended goal of therapy. The trial’s 2-year clinical outcome (n=366) demonstrated superiority of the HM3 for the primary end point (survival free of a disabling stroke or reoperation to replace or remove a malfunctioning pump). This analysis evaluates health resource use and cost implications of the observed differences between the 2 devices while patients were enrolled in the trial.Methods:We analyzed all hospitalizations and their associated costs occurring after discharge from the implant hospitalization until censoring (study withdrawal, heart transplantation, and pump exchange with a nonstudy device or death). Each adjudicated episode of hospital-based care was used to calculate costs (device-attributable and non–device-attributable event costs), estimated by using trial data and payer administrative claims databases. Cost savings stratified by subgroups (study outcome [transplant, death, or ongoing on device], intended goal of therapy, type of insurance, or sex) were also assessed.Results:In 366 randomly assigned patients, 361 comprised the as-treated group (189 in the HM3 group and 172 in the HMII group), of whom 337 (177 in the HM3 group and 160 in the HMII group) were successfully discharged following implantation. The HM3 arm experienced fewer total hospitalizations per patient-year (HM3: 2.1±0.2 versus HMII: 2.7±0.2; P=0.015) and 8.3 fewer hospital days per patient-year on average (HM3: 17.1 days versus HMII: 25.5 days; P=0.003). These differences were driven by patients hospitalized for suspected pump thrombosis (HM3: 0.6% versus HMII: 12.5%; P<0.001) and stroke (HM3: 2.8% versus HMII: 11.3%; P=0.002). Controlled for time spent in the study (average cumulative cost per patient-year), postdischarge HM3 arm costs were 51% lower than with the HMII (HM3: $37 685±4251 versus HMII: $76 599±11 889, P<0.001) and similar in either bridge to transplant or destination therapy intent.Conclusions:In this 2-year outcome economic analysis of the MOMENTUM 3 trial, the HM3 demonstrated a reduction in rehospitalizations, hospital days spent during rehospitalizations, and a significant cost savings following discharge in comparison with the HMII left ventricular assist system, irrespective of the intended goal of therapy.Clinical Trial Registration:URL: https://www.clinicaltrials.gov. Unique identifier: NCT02224755.